BOARD OF DIRECTORS

The Board of Directors of Biosys UK Limited combines expertise across industry, academia, drug development and the investment community, unified by a mission to improve the lives of patients

Sacha Mann, MSc, MBA: CEO and Director

Sacha is the CEO of Biosys UK Limited and brings a strong mix of operational skills and financial discipline to her current role. Most recently, Sacha was with Inventages leading life science investments focused on the microbiome, GI disorders, CNS, anti-infectives, inflammatory diseases, metabolic disorders, vaccines, and point of care diagnostics. Prior to Inventages, Sacha was an early stage investor focused on innovation, company formation and investment in the UK (Archangels) and Canada (BDC Capital). Sacha was also directly involved in establishing university spin-offs and has experience in biotech business development, corporate finance, management consultancy and R&D. Sacha has an MBA (Simon Fraser University), an MSc in biotechnology (Johns Hopkins University), a BSc in chemistry (University of British Columbia), and is a Kauffman Fellow.

Gunnar Weikert, MD, PhD, MBA: Non-executive Director

Gunnar is the Chairman and Founder of Inventages, one of the world’s largest specialised life science investors. He was previously a Senior VP at Bayer AG, and has more than 20 years experience in the life sciences industry.

Axel Wiest, MD, PhD, MPH: Non-executive Director

Axel is a senior executive with several years of experience in the biopharmaceutical and healthcare industries. He is currently SVP/COO R&D and Head of Global Strategy and Business Operations R&D at Merck Biopharma. Previously he held leadership roles at Boehringer Ingelheim Biopharmaceuticals and Fresenius. 

Matthew Edwards, BA, LLB: Non-executive Director

Matthew is General Counsel at Inventages. Prior to joining Inventages, Matthew was a Special Counsel at Covington & Burling LLP, advising clients on mergers and acquisitions, IPOs and other securities issues, as well as corporate finance and venture capital transactions, with a particular focus on the life sciences and technology sectors.